Table 1 -.
Patient and procedural characteristics according to hemoglobin and platelet status (N=120,348)*
| Isolated thrombocytopenia |
|||||
|---|---|---|---|---|---|
| Normal (n=87,046) | Isolated anemia (n=31,709) | Non-incidental (n=454) | Incidental (n=171) | Thrombocytopenia and anemia (n=968) | |
| Patient and procedural characteristics | |||||
| Age (years) | 61 (51, 70) | 65 (53, 74) | 63 (51, 71) | 62 (52, 71) | 64 (54, 73) |
| Sex | |||||
| Male | 42,490 (49%) | 18,419 (58%) | 264 (58%) | 111 (65%) | 680 (70%) |
| Female | 44,556 (51%) | 13,290 (42%) | 190 (42%) | 60 (35%) | 288 (30%) |
| ASA PS (n=118,872) | |||||
| 1–2 | 51,582 (60%) | 12,654 (40%) | 143 (32%) | 58 (34%) | 231 (24%) |
| 3–4† | 34,463 (40%) | 18,599 (60%) | 307 (68%) | 112 (66%) | 723 (76%) |
| Procedure type | |||||
| Orthopedic | 27,943 (32%) | 7,814 (25%) | 94 (21%) | 36 (21%) | 165 (17%) |
| General | 16,601 (19%) | 8,866 (28%) | 134 (30%) | 57 (33%) | 359 (37%) |
| Cardiac | 8,987 (10%) | 2,989 (9%) | 68 (15%) | 21 (12%) | 91 (9%) |
| Vascular | 1,596 (2%) | 976 (3%) | 10 (2%) | 3 (2%) | 38 (4%) |
| Transplant | 1,430 (2%) | 1,092 (3%) | 13 (3%) | 1 (1%) | 70 (7%) |
| Other procedure type | 30,489 (35%) | 9,972 (31%) | 135 (30%) | 53 (31%) | 245 (25%) |
| Type of anesthetic | |||||
| General | 74,750 (86%) | 27,976 (88%) | 418 (92%) | 161 (94%) | 881 (91%) |
| Regional | 10,736 (12%) | 2,752 (9%) | 19 (4%) | 4 (2%) | 28 (3%) |
| Monitored anesthesia care | 1,073 (1%) | 692 (2%) | 7 (2%) | 6 (4%) | 51 (5%) |
| Comorbidities | |||||
| Charlson score | 4 (2, 5) | 5 (3, 7) | 5 (3, 7) | 5 (3, 7) | 6 (4, 9) |
| Cancer | 24,704 (28%) | 11,841 (37%) | 124 (27%) | 61 (36%) | 366 (38%) |
| Renal disease | 3,137 (4%) | 4,822 (15%) | 40 (9%) | 8 (5%) | 176 (18%) |
| Cerebrovascular accident | 3,024 (3%) | 1,998 (6%) | 28 (6%) | 4 (2%) | 53 (5%) |
| Myocardial infarction | 2,829 (3%) | 2,146 (7%) | 28 (6%) | 10 (6%) | 71 (7%) |
| Chronic heart failure | 2,137 (2%) | 1,722 (5%) | 23 (5%) | 6 (4%) | 61 (6%) |
| Lymphoma | 1,297 (1%) | 1,086 (3%) | 36 (8%) | 7 (4%) | 157 (16%) |
| Liver disease | 812 (1%) | 699 (2%) | 116 (26%) | 33 (19%) | 234 (24%) |
| Leukemia | 441 (1%) | 372 (1%) | 24 (5%) | 9 (5%) | 93 (10%) |
| Pre-operative laboratory values and medications | |||||
| Hemoglobin (g/dL) | 14.1 (13.4, 14.9) | 11.6 (10.7, 12.5) | 14.0 (13.2, 14.7) | 14.3 (13.5, 15.0) | 11.0 (9.9, 12.1) |
| Platelet count (×109 per μL) | 231 (194, 274) | 239 (190, 305) | 78 (62, 90) | 90 (80, 95) | 77 (59, 90) |
| Creatinine (mg/dL; n=101,340) | 0.9 (0.8, 1.1) | 1.0 (0.8, 1.2) | 0.9 (0.8, 1.1) | 0.9 (0.8, 1.1) | 1.0 (0.8, 1.3) |
| INR (n=35,659) | 1.0 (1.0, 1.1) | 1.1 (1.0, 1.2) | 1.1 (1.0, 1.3) | 1.1 (1.0, 1.3) | 1.1 (1.1, 1.3) |
| Anti-platelets‡ | 46,897 (54%) | 16,264 (51%) | 169 (37%) | 74 (43%) | 358 (37%) |
| Anticoagulants¥ | 12,514 (14%) | 6,811 (21%) | 88 (19%) | 31 (18%) | 211 (22%) |
*
Values are number (percentage) for categorical variables and median (25th percentile, 75th percentile) for continuous variables. When not all data are available, numbers with complete data are presented. Anesthetic type missing for 1% (1,452).
†
Twenty-four patients were classified as ASA PS 5 or 6.
‡
Includes aspirin and clopidogrel
¥
Includes warfarin, unfractionated and low molecular weight heparin, factor Xa inhibitors, direct thrombin inhibitors,
Abbreviations: ASA PS = American society of anesthesiologists physical status; INR = International normalized ratio